Correlating RANK Ligand/RANK Binding Kinetics with Osteoclast Formation and Function

Journal of Cellular Biochemistry

Volumn 116, Issue 11, 2015, Pages 2476-2483

  Warren, Julia T ^a   Zou, Wei ^a   Decker, Corinne E ^a   Rohatgi, Nidhi ^a   Nelson, Christopher A ^a   Fremont, Daved H ^a   Teitelbaum, Steven L ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Medicine ^*  (United States)

Author keywords

BONE; KINETICS; OSTEOCLAST; RANK; RANKL; RECEPTOR; SIGNAL TRANSDUCTION; TNF SUPERFAMILY

Indexed keywords

CYTOKINE; MUTANT PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TUMOR NECROSIS FACTOR; PROTEIN BINDING; RECOMBINANT PROTEIN; TNFRSF11A PROTEIN, MOUSE; TNFRSF11B PROTEIN, MOUSE; TNFSF11 PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; BINDING KINETICS; BONE MARROW; CELL LINEAGE; CONTROLLED STUDY; MACROPHAGE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; YEAST; ANIMAL; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; GENETICS; KINETICS; METABOLISM; MUTATION; SIGNAL TRANSDUCTION;

ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; KINETICS; MACROPHAGES; MICE; MUTATION; OSTEOCLASTS; OSTEOPROTEGERIN; PROTEIN BINDING; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION;

EID: 84941136485     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.25191     Document Type: Article

References (47)

1. Abu-Amer Y, Erdmann J, Alexopoulou L, Kollias G, Ross FP, Teitelbaum SL,. 2000. Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis. J Biol Chem 275 (35): 27307-27310.
2. Abu-Amer Y, Ross FP, Edwards J, Teitelbaum SL,. 1997. Li popolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor. J Clin Invest 100 (6): 1557-1565.
3. Aggarwal BB, Gupta SC, Kim JH,. 2012. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 119 (3): 651-665.
4. Aricescu AR, Lu W, Jones EY,. 2006. A time- and cost-efficient system for high-level protein production in mammalian cells. Acta Crystallographica. Section D: Biological Crystallography 62 (Pt 10): 1243-1250.
5. Asagiri M, Takayanagi H,. 2007. " The molecular understanding of osteoclast differentiation. Bone 40 (2): 251-264.
6. Ban L, Zhang J, Wang L, Kuhtreiber W, Burger D, Faustman DL,. 2008. " Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism. Proc Natl Acad Sci USA 105 (36): 13644-13649.
7. Blair HC, Robinson LJ, Zaidi M,. 2005. Osteoclast signalling pathways. Biochem Biophys Res Commun 328 (3): 728-738.
8. Bodmer JL, Schneider P, Tschopp J,. 2002. The molecular architecture of the TNF superfamily. Trends Biochem Sci 27 (1): 19-26.
9. Boschert V, Krippner-Heidenreich A, Branschadel M, Tepperink J, Aird A, Scheurich P,. 2010. Single chain TNF derivatives with individually mutated receptor binding sites reveal differential stoichiometry of ligand receptor complex formation for TNFR1 and TNFR2. Cell Signal 22 (7): 1088-1096.
10. Cabal-Hierro L, Lazo PS,. 2012. Signal transduction by tumor necrosis factor receptors. Cell Signal 24 (6): 1297-1305.
11. Chervin AS, Stone JD, Holler PD, Bai A, Chen J, Eisen HN, Kranz DM,. 2009. The impact of TCR-binding properties and antigen presentation format on T cell responsiveness. J Immunol 183 (2): 1166-1178.
12. Cheung TC, Coppieters K, Sanjo H, Oborne LM, Norris PS, Coddington A, Granger SW, Elewaut D, Ware CF,. 2010. Polymorphic variants of LIGHT (TNF superfamily-14) alter receptor avidity and and bioavailability. J Immunol 185 (3): 1949-1958.
13. Croft M,. 2009. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 9 (4): 271-285.
14. Croft M, Benedict CA, Ware CF,. 2013. Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov 12 (2): 147-168.
15. Ebach DR, Riehl TE, Stenson WF,. 2005. Opposing effects of tumor necrosis factor receptor 1 and 2 in sepsis due to cecal ligation and puncture. Shock 23 (4): 311-318.
16. Faustman D, Davis M,. 2010. TNF receptor 2 pathway: drug target for autoimmune diseases. Nat Rev Drug Discov 9 (6): 482-493.
17. Hanada R, Hanada T, Penninger JM,. 2010. Physiology and pathophysiology of the RANKL/RANK system. Biol Chem 391 (12): 1365-1370.
18. Hehlgans T, Pfeffer K,. 2005. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 115 (1): 1-20.
19. Henkler F, Behrle E, Dennehy KM, Wicovsk A, Peters N, Warnke C, Pfizenmaier, Wajant H,. 2005. The extracellular domains of FasL and Fas are sufficient for the formation of supramolecular FasL-Fas clusters of high stability. J Cell Biol 168 (7): 1087-1098.
20. Holler N, Tardivel A, Kovacsovics-Bankowski M, Hertig S, Gaide O, Martinon F, Tinel A, Deperthes D, Calderara S, Schulthess T, Engel J, Schneider P, Tschopp J,. 2003. Two Adjacent Trimeric Fas Ligands Are Required for Fas Signaling and Formation of a Death-Inducing Signaling Complex. Mol Cell Biol 23 (4): 1428-1440.
21. Irving M, Zoete V, Hebeisen M, Schmid D, Baumgartner P, Guillaume P, Romero P, Speiser D, Leuscher I, Rufer N, Michielin O,. 2012. Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. J Biol Chem 287 (27): 23068-23078.
22. Jiang D, Chen Y, Schwarz H,. 2008. CD137 induces proliferation of murine hematopoietic progenitor cells and differentiation to macrophages. J Immunol 181 (6): 3923-3932.
23. Kontermann RE, Munkel S, Neumeyer J, Muller D, Branschadel M, Scheurich P, Pfizenmaier K,. 2008. A humanized tumor necrosis factor receptor 1 (TNFR1)-specific antagonistic antibody for selective inhibition of tumor necrosis factor (TNF) action. J Immunother 31 (3): 225-234.
24. Levin AM, Bates DL, Ring AM, Krieg C, Lin JT, Su L, Moraga I, Raeber ME, Bowman GR, Novick P, Pande VS, Fathman CG, Boyman O, Garcia KC,. 2012. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature 484 (7395): 529-533.
25. Li J, Yin Q, Wu H,. 2013. Structural basis of signal transduction in the TNF receptor superfamily. Adv Immunol 119: 135-153.
26. Mackay F, Schneider P,. 2009. Cracking the BAFF code. Nat Rev Immunol 9 (7): 491-502.
27. Mukai Y, Shibata H, Nakamura T, Yoshioka Y, Abe Y, Nomura T, Taniai M, Ohta T, Ikemizu S, Nakagawa S, Tsunoda S, Kamada H, Yamagata Y, Tsutsumi Y,. 2009. Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant. J Mol Biol 385 (4): 1221-1229.
28. Nagano K, Alles N, Mian AH, Shimoda A, Morimoto N, Tamura Y, Shimokawa H, Akiyoshi K, Ohya K, Aoki K,. 2011. The tumor necrosis factor type 2 receptor plays a protective role in tumor necrosis factor-alpha-induced bone resorption lacunae on mouse calvariae. J Bone Miner Metab 29 (6): 671-681.
29. Nelson CA, Warren JT, Wang MW, Teitelbaum SL, Fremont DH,. 2012. " RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor. Structure 20 (11): 1971-1982.
30. Novack DV, Teitelbaum SL,. 2008. The osteoclast: friend or foe? Annu Rev Pathol 3: 457-484.
31. Peschon JJ, Torrance DS, Stocking KL, Glaccum MB, Otten C, Willis CR, Charrier K, Morrissey PJ, Ware CB, Mohler KM,. 1998. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 160 (2): 943-952.
32. Schmid DA, Irving MB, Posevitz V, Hebeisen M, Posevitz-Fejfar A, Sarria JC, Gomez-Eerland R, Thome M, Schumacher TN, Romero P, Speiser DE, Zoete V, Michielin O, Rufer N,. 2010. Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol 184 (9): 4936-4946.
33. Selmaj K, Raine CS, Cross AH,. 1991. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Annals of Neurol 30 (5): 694-700.
34. Siegel RM, Muppidi JR, Sarker M, Lobito A, Jen M, Martin D, Straus SE, Lenardo MJ,. 2004. SPOTS: Signaling protein oligomeric transduction structures are early mediators of death receptor-induced apoptosis at the plasma membrane. J Cell Biol 167 (4): 735-744.
35. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gregg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ,. 1997. Osteoprotegerin: A novel secreted protein involved in the regulation of bone. Cell 89 (2): 309-319.
36. Sudhamsu J, Yin J, Chiang EY, Starovasnik MA, Grogan JL, Hymowitz SG,. 2013. Dimerization of LTbetaR by LTalpha1beta2 is necessary and sufficient for signal transduction. Proc Natl Acad Sci USA 110 (49): 19896-19901.
37. Summers deLuca L, Gommerman JL,. 2012. Fine-tuning of dendritic cell biology by the TNF superfamily. Nat Rev Immunol 12 (5): 339-351.
38. Takeshita S, Kaji K, Kudo A,. 2000. Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. J Bone Miner Res 15: 1477-1488.
39. Upadhyay V, Fu YX,. 2013. Lymphotoxin signalling in immune homeostasis and the control of microorganisms. Nat Rev Immunol 13 (4): 270-279.
40. Valitutti S, Muller S, Cella M, Padovan E, Lanzavecchia A,. 1995. Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature 375 (6527): 148-151.
41. Vujanovic NL,. 2011. Role of TNF superfamily ligands in innate immunity. Immunol Res 50 (2-3): 159-174.
42. Warren JT, Nelson CA, Decker CE, Zou W, Fremont DH, Teitelbaum SL,. 2014. Manipulation of receptor oligomerization as a strategy to inhibit signaling by TNF superfamily members. Sci Signal 7 (339): ra80.
43. Wu H,. 2013. Higher-order assemblies in a new paradigm of signal transduction. Cell 153 (2): 287-292.
44. Wu H, Hymowitz SG,. 2010. Structure and Function of Tumor Necrosis Factor (TNF) at the Cell Surface. Handbook of Cell Signaling (Second Edition), Academic Press. 1: 265-275.
45. Yamaguchi K, Kinosaki M, Goto M, Kobayashi F, Tsuda E, Morinaga T, Higashio K,. 1998. " Ch aracterization of structural domains of human osteoclastogenesis inhibitory factor.". J Biol Chem 273 (9): 5117-5123.
46. Zauli G, Secchiero P,. 2006. The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. Cytokine Growth Factor Rev 17 (4): 245-257.
47. Zhu M, Fu YX,. 2011. The role of core TNF/LIGHT family members in lymph node homeostasis and remodeling. Immunol Rev 244 (1): 75-84.